Addition Therapeutics
The role involves designing, developing, validating, and executing in vitro, cell‑based, and ex vivo bioanalytical assays to evaluate the efficacy and pharmacology of PRINT™‑delivered payloads for obesity and metabolic disease programs. The scientist will generate quantitative data to support PK/PD characterization, IND‑enabling studies, and translational efforts, collaborating closely with cross‑functional teams.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Addition Therapeutics.
14% above the average for this role
Product Development Scientist
AstraZeneca
Associate Scientist - Oncology In Vivo Pharmacology
Bristol Myers Squibb
Associate Scientist, In Vivo Pharmacology
Bristol Myers Squibb
Associate Scientist
Medicilon Inc
Research Associate/ Associate Scientist, Nonclinical Development
Adicet Bio
Associate Scientist
Servier